Effects of TNF, NOS3, MDR1 Gene Polymorphisms on Clinical Parameters, Prognosis and Survival of Multiple Myeloma Cases


Department of Hematology, Gaziantep University Faculty of Medicine, Gaziantep,Turkey


It is not clear how gene polymorphisms affecting drugs can contributes totheir efficacy in multiple myeloma (MM). We here aimed to explore associations among gene polymorphisms of tumor necrosis factor alpha (TNF), nitric oxide synthesis 3 (NOS3) and multi-drug resistance 1 (MDR1), clinical parameters, prognosis and survival in MM patients treated with VAD (vincristine-adriamycine-dexamethasone), MP (mephalane-prednisolone), autolougus stem cell transplantation (ASCT), BODEC (bortezomib-dexamethasone-cyclophosphamide) and TD (thalidomide-dexamethasone). We analyzed TNF, NOS 3 and MDR1 in 77 patients with MM and 77 healthy controls. The genotyping was performed with PCR and/or PCR-RFLP. There was no clinically significant difference between MM and control groups when TNF (-238) and (-857) and MDR1 gene polymorphisms were studied. However, the TNFgene polymorphism (-308) GG genotype (p=0.012) and NOS3 (894) TT genotype (p=0.008) were more common in the MM group compared to healthy controls. NOS3 (VNTR) AA (p=0.007) and NOS3 (894) GG genotypes (p=0.004) were decreased in the MM group in contrast. In conclusion, the NOS3 (894) TT and TNF (-308) GG genotypes may have roles in myeloma pathogenesis.